This Article Full Text Full Text (PDF) All Versions of this Article: 25/6/1193    most recent 01.ATV.0000163844.07815.c4v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arakawa, R. Articles by Yokoyama, S. Search for Related Content PubMed PubMed Citation Articles by Arakawa, R. Articles by Yokoyama, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Lipids Cardiovascular Pharmacology Primary prevention Secondary prevention Lipid and lipoprotein metabolism Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1193.)
© 2005 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Fenofibric Acid, an Active Form of Fenofibrate, Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by Enhancing Transcription of ATP-Binding Cassette Transporter A1 Gene in a Liver X Receptor–Dependent Manner

Reijiro Arakawa; Norimasa Tamehiro; Tomoko Nishimaki-Mogami; Kazumitsu Ueda; Shinji Yokoyama

From the Department of Biochemistry, Cell Biology, and Metabolism (R.A., S.Y.), Nagoya City University Graduate School of Medical Sciences, Japan; Research and Development Institute (R.A.), Grelan Pharmaceutical Co., Tokyo, Japan; Division of Biosignaling (N.T., T.N.-M.), National Institute of Health Sciences, Tokyo, Japan; and Division of Applied Life Sciences (K.U.), Graduate School of Agriculture, Kyoto University, Japan.

Correspondence to Shinji Yokoyama, Department of Biochemistry, Cell Biology, and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan. E-mail syokoyam{at}med.nagoya-cu.ac.jp

Objective— Fibrates are widely used drugs to reduce plasma triglyceride and increase high-density lipoprotein. Their active forms, fibric acids, are peroxisome proliferator-activated receptor- activators, but no direct evidence has been demonstrated for their activation of ATP-binding cassette transporter A1 (ABCA1) in relation to clinically used fibrates. We investigated the reaction of fenofibric acid in this regard.

Methods and Results— Fenofibric acid was examined for the effect of increase of ABCA1 activity. It enhanced ABCA1 gene transcription and its protein level in macrophage cell line cells and fibroblasts and increased apolipoprotein A-I–mediated cellular lipid release, all in a dose-dependent manner. Enhancement of the gene transcription was examined by using a reporter assay system for liver X receptor responsive element (LXRE) and its inactive mutant. The results demonstrated that the effect of fenofibric acid is dependent on active LXRE.

Conclusions— Fenofibric acid increased transcription of ABCA1 gene in a liver X receptor–dependent manner.

Fibrates are widely used drugs to reduce plasma triglyceride and increase high-density lipoprotein. Their active forms, fibric acids, are peroxisome proliferator-activated receptor- activators, but no direct evidence has been demonstrated for their activation of ATP-binding cassette transporter A1 (ABCA1) in relation to clinically used fibrates. We investigated the reaction of fenofibric acid in this regard, finding that fenofibric acid increased transcription of ABCA1 gene in n liver X receptor–dependent manner.

Key Words: fenofibrate • fibrates • PPAR • ABCA1 • HDL • cholesterol • atherosclerosis

Related Article:

Antiatherogenic Properties of Fibrates

P.J. Barter
Arterioscler Thromb Vasc Biol 2005 25: 1095-1096. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				R. Simo and C. Hernandez Advances in the Medical Treatment of Diabetic Retinopathy Diabetes Care, August 1, 2009; 32(8): 1556 - 1562. [Full Text] [PDF]

				R. Lu, R. Arakawa, C. Ito-Osumi, N. Iwamoto, and S. Yokoyama ApoA-I Facilitates ABCA1 Recycle/Accumulation to Cell Surface by Inhibiting Its Intracellular Degradation and Increases HDL Generation Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1820 - 1824. [Abstract] [Full Text] [PDF]

				A. T. Remaley Old Drug, New Tricks: The Unexpected Effect of Doxazosin on High-Density Lipoprotein Circ. Res., July 20, 2007; 101(2): 116 - 118. [Full Text] [PDF]

				N. Iwamoto, S. Abe-Dohmae, M. Ayaori, N. Tanaka, M. Kusuhara, F. Ohsuzu, and S. Yokoyama ATP-Binding Cassette Transporter A1 Gene Transcription Is Downregulated by Activator Protein 2{alpha}: Doxazosin Inhibits Activator Protein 2{alpha} and Increases High-Density Lipoprotein Biogenesis Independent of {alpha}1-Adrenoceptor Blockade Circ. Res., July 20, 2007; 101(2): 156 - 165. [Abstract] [Full Text] [PDF]

				2nd International Symposium on Triglycerides and HDL: Lipid abnormalities and their treatment Diabetes Care, November 1, 2005; 28(11): 2795 - 2802. [Full Text] [PDF]

				M. Hayashi, S. Abe-Dohmae, M. Okazaki, K. Ueda, and S. Yokoyama Heterogeneity of high density lipoprotein generated by ABCA1 and ABCA7 J. Lipid Res., August 1, 2005; 46(8): 1703 - 1711. [Abstract] [Full Text] [PDF]

				P.J. Barter Antiatherogenic Properties of Fibrates Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1095 - 1096. [Full Text] [PDF]